These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Inhibition of herpes simplex virus replication by anthracycline compounds.
    Author: Ash RJ, Diekema KA.
    Journal: Antiviral Res; 1987 Sep; 8(2):71-83. PubMed ID: 2830845.
    Abstract:
    The replication of type 1 and type 2 strains of herpes simplex virus (HSV) was inhibited greater than 99.9% by low concentrations (0.1-0.2 microM) of anthracycline compounds. The degree of viral inhibition was dependent upon the host cell. N,N-dimethyl daunomycin (NDMD), a non-mutagenic compound, was more potent as an inhibitor of HSV synthesis than either daunomycin (DM) or adriamycin (AD). The depression of viral yield by DM or AD was attributable, in part, to a temperature-dependent direct effect on infectious virions. Tritium-labeled DM bound tightly to HSV particles. NDMD did not directly inactivate virions in spite of superior potency in reducing viral yields. All three anthracyclines could be added late in the infectious cycle (6-8 h p.i.) and retain effectiveness. Cesium chloride density gradient analysis verified that viral DNA synthesis was blocked by addition of all three anthracyclines early in the infectious cycle. The inhibition of HSV replication was not a simple consequence of the suppression of host DNA synthesis since treatment of cells with compounds for 24 h before infection did not reduce virus yields even though host DNA synthesis was inhibited by 90%. Further, the kinetics of inhibition of cellular DNA synthesis by anthracyclines was similar in HFF or Vero cells but the degree of inhibition of virus replication was markedly different. The data suggest that anthracyclines with substitutions on the sugar moiety may be useful anti-herpes agents.
    [Abstract] [Full Text] [Related] [New Search]